- Home
- TRGP vs ZTS Comparison
TRGP vs ZTS Comparison
Compare TRGP & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRGP | ZTS |
|---|---|---|
| Founded | 2005 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.1B | 54.8B |
| IPO Year | 2010 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TRGP | ZTS |
|---|---|---|
| Price | $225.50 | $127.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $212.17 | $156.20 |
| AVG Volume (30 Days) | 1.3M | ★ 4.3M |
| Earning Date | 05-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.23% | 1.67% |
| EPS Growth | ★ 47.91 | 10.05 |
| EPS | ★ 8.49 | 6.02 |
| Revenue | ★ $17,028,300,000.00 | $9,467,000,000.00 |
| Revenue This Year | $41.12 | $5.79 |
| Revenue Next Year | $4.81 | $5.16 |
| P/E Ratio | $26.41 | ★ $21.14 |
| Revenue Growth | ★ 3.95 | 2.28 |
| 52 Week Low | $144.14 | $115.25 |
| 52 Week High | $232.86 | $177.00 |
Technical Indicators
Market Signals| Indicator | TRGP | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 76.64 | 53.52 |
| Support Level | $217.79 | $124.50 |
| Resistance Level | $205.93 | $132.49 |
| Average True Range (ATR) | 5.96 | 4.08 |
| MACD | 1.37 | 0.20 |
| Stochastic Oscillator | 80.70 | 61.84 |
Price Performance
Historical ComparisonAbout TRGP Targa Resources Inc.
Targa Resources is a midstream firm that primarily operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.